-
Ginkgo biloba for Acute Mountain Sickness
|
|
-
Ginkgo biloba for Atherosclerosis
|
|
-
Ginkgo biloba for Mild Cognitive Impairment
|
Moderately Positive
|
Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.
|
Moderately Positive
|
EGb 761® improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.
|
Moderately Positive
|
EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.
|
Moderately Positive
|
GBT tablet can improve the therapeutic efficacy as well improve cognitive ability and cerebral blood flow supply of patients with VCIND.
|
Moderately Positive
|
In conclusion, treatment with EGb 761(®) at a once-daily dose of 240 mg was safe and resulted in a significant and clinically relevant improvement in cognition, psychopathology, functional measures and quality of life of patients and caregivers.
|
Moderately Positive
|
Long-term use of standardised ginkgo biloba extract in this trial did not reduce the risk of progression to Alzheimer's disease compared with placebo.
|
Moderately Positive
|
No differences in the number of (gastrointestinal) side effects were observed between placebo and verum groups. These results indicate that the use of Ginkgo extracts in elderly individuals with cognitive impairment might be promising. Further research using both subjective and objective measurements is recommended.
|
Moderately Positive
|
The data add further evidence on the safety and efficacy of EGb 761 in the treatment of cognitive and non-cognitive symptoms of dementia.
|
Moderately Positive
|
The frequency of therapy responders in the two treatment groups differed significantly in favor of EGb 761, with p < 0.005 in Fisher's Exact Test. The intent-to-treat analysis of 205 patients led to similar efficacy results. Thus, the clinical efficacy of the ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type and multi-infarct dementia was confirmed. The investigational drug was found to be well tolerated.
|
Moderately Positive
|
These exploratory findings helped to develop three hypotheses that will have to be proven in further studies: (1) there is no significant difference in the efficiency between EGb 761(R) and donepezil, (2) a combination therapy will be superior to a mono-therapy with one of both substances and (3) there will be less side effects under a combination therapy than under mono-therapy with donepezil.
|
|
-
Ginkgo biloba for Proteinuria
|
|
|
|
-
Ginkgo biloba for Alzheimer's Disease
|
|
-
Ginkgo biloba for Anxiety
|
|
-
Ginkgo biloba for Intermittent Claudication
|
|
-
Ginkgo biloba for Oxidative Damage
|
|
-
Ginkgo biloba for Peripheral Arterial Disease
|
|
-
Ginkgo biloba for Pinkeye
|
|
-
Ginkgo biloba for Premenstrual Syndrome
|
|
-
Ginkgo biloba for Schizophrenia
|
|
-
Ginkgo biloba for Skin Aging
|
|
|
|
-
Ginkgo biloba for Tardive Dyskinesia
|
|
-
Ginkgo biloba for Vitiligo
|
|
-
Ginkgo biloba for Breast Cancer
|
|